RHP 5.54MTRN 4.28PSMT 0ESLOY 0MSFT -8.48META -4.53HLPR.TO 0VDY.TO -0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

24.04
-0.68 (2.75%)
as of Jun 24, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges including a patent cliff and the aftermath of over-earning during the COVID-19 pandemic. The company has made efforts to bolster its drug pipeline through acquisitions, such as Seagen, but many experts express concerns about the lack of earnings momentum and blockbusters to drive growth. While the stock offers an attractive dividend yield (around 6-7%), there is a prevailing sentiment around its long-term growth prospects as reliance on cost-cutting and strategic acquisitions seems insufficient. Analysts highlight the need for a new growth catalyst, particularly in oncology, to reassure investors as the dividend yield may be at risk if substantial progress with new drugs is not achieved. Overall, patience is emphasized by many experts, with a hope that the stock will eventually perform better amid potential improvements in government policies and market conditions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
AstraZeneca, AZN
DON'T BUY

Pfizer Inc(PFE)

Aug 21, 2008
Pharmaceutical group is behaving better. This one is less attractive and is facing drugs coming off patent. Prefers others.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$19.37

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 06, 2008
Earnings where fantastic. Yield of 6.6%.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$19.43

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jul 16, 2008
At an interesting Buy point but not sure he would buy it currently. On his Watch list.
Photo of Peter BriegerPeter Brieger
No
Unlock Rating
$18.26

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jul 11, 2008
(Market Call Minute.) Broken stock and he can't see what is going to turn it around.
Photo of David BurrowsDavid BurrowsUnlock Rating
$17.81

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 10, 2008
All of the big pharma have been very disappointing. Now yielding over 7% but doesn't think the dividend is in jeopardy as the cash flow is amazingly strong. Won't be a great investment for another year or so.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$18.03

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 04, 2008
Not cheap enough for him yet. He would have to go over the financial statements. There are a lot of companies in this area that may be of interest in the next few years.
Photo of Benj GallanderBenj Gallander
No
Unlock Rating
$17.75

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 11, 2008
Model price has been decreasing over the last 9 months, but not all that much. Thinks it will go down to $15.75 but he sees in setting up as a huge rally in healthcare related stocks in Q4 or Q1 of 09. Has an 86% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$17.55

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 10, 2008
Pharmaceutical industry in the US has been a disappointment for 2 or 3 years. There is concern about the new drug pipeline. Also a large number of blockbuster drugs are coming off patent for many companies. Also increased competition from generic companies. At 7.2%, the market is telling you it does not believe the dividend is safe.
Photo of David BaskinDavid BaskinUnlock Rating
$17.94

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
DON'T BUY

Pfizer Inc(PFE)

Jun 09, 2008
Its problem, along with many of the health care companies in the US, is the pipeline. Lipitor, which is a large portion of their revenues, comes off patent next year. Have lots of cash flow but haven't been able to take advantage to develop anything. Would buy Novo-Nordisk (NVO-N) instead.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$18.02

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 05, 2008
From his perspective, it has absolutely technically broken down. Looks like almost everything is going against it. Also, it is likely Democrats will come to power and won't be helpful to the drug companies.
Photo of Ross HealyRoss Healy
No
Unlock Rating
$18.67

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jun 03, 2008
6.73% dividend. Doesn't see a lot of prospects in their pipeline. Some of their big money makers are in a lot of jeopardy from competition. If you like pharmaceuticals, consider moving into Johnson & Johnson (JNJ-N).
Photo of Duncan StewartDuncan Stewart
No
Unlock Rating
$19.01

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jun 02, 2008
Product portfolio continues to undergo greater competition from generics. New products are declining. Still haven't turned the corner. Generics such as Teva Pharmaceutical (TEVA-Q) would be more attractive.
Photo of David GarrityDavid Garrity
No
Unlock Rating
$19.18

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 21, 2008
Candidates in the presidential race have not been positive on pharmaceutical companies. The problem with this company however is the lack of a pipeline. Most of the earnings are coming from some products that are going to go off patent in the next couple of years. Has become more and more expensive to generate new drugs. The dividend could be a potential trap and could be lowered.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$20.01

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

May 15, 2008
6.5% dividend yield. Cash flows are very strong.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$20.08

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 14, 2008
Recently sold his holdings. A lot of their pipeline is going into generic distribution, which will take a lot of revenue off the top line. Feels the 6% dividend is probably safe.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$20.06

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 511 to 525 of 883 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -8.48$365.46
PPL.TO -0.83$66.15
CVE.TO -1.49$35.09
TOU.TO -0.68$59.86
GOOG -1.04$345.04

Today's Top Picks

RHP 5.54$129.77
MTRN 4.28$269.62
PSMT 0$
ESLOY 0$95.66
MSFT -8.48$365.46

Popular Articles

Latest Sell Signals

ATD.TO 1.89$93.76
ITB 5.99$103.32
GLD -11.4$365.92
MU -3.26$1048.51
MU -3.26$1048.51

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica